FS-102 is under clinical development by F-star Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect FS-102’s likelihood of approval (LoA) and phase transition for Adenocarcinoma Of The Gastroesophageal Junction took place on 27 Oct 2020, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 27 Oct 2020 decreased FS-102’s LoA and PTSR for Gastric Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their FS-102 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

FS-102 overview

FS-102 is under development for the treatment of solid tumors including HER2+ breast cancer, gastric cancer and gastroesophageal junction adenocarcinoma. It is administered intravenously. The drug candidate is developed based on Fcab (an Fc-domain with antigen binding sites) technology. The antibody targets human epidermal growth factor receptor 2 (HER-2). It was also under development for the treatment of colorectal cancer.

F-star Therapeutics overview

F-star Therapeutics, formerly Spring Bank Pharmaceuticals Inc, is a clinical-stage biopharmaceutical company. It discovers and develops novel class of therapeutics. The company develops nucleotide-based drugs and small molecule nucleic acid hybrids. Its development pipeline products include FS118, FS120, FS222, SB 11285, among other drug candidates. The company’s drug products are used in the rescuing CPI treatment failures, improving outcomes in CPI naive, PD-L1 low tumors, chemotherapy outcomes, CPI outcomes, addressing unmet needs. Its partners programs include multiple blood brain barrier, multiple immuno-oncology, STING inhibitor, multiple next generation bispecifics. Spring Bank is headquartered in Hopkinton, Massachusetts, the US.

Quick View FS-102 LOA Data

Report Segments
  • Innovator
Drug Name
  • FS-102
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.